Successful application of our discovery antibody microarrays in a study on bladder cancer:

In the study more than 100 biomarker candidates were identified for a prognosis of recurrence in non-muscle invasive bladder cancer. A  multivariate classifier was constructed that is based on the expression variation of 20 proteins and facilitates the prediction of recurrence with a sensitivity of 80% at a specificity of 100%.

Further informations:

Latest Scientific Publications using scioCD

Article | Altered Serum Proteins indicate Inflammation, Fibrogenesis and Angiogenesis in Fontan Patients

| September 2024 | Four identified serum proteins may advance diagnostic and therapeutic approaches by complementing traditional diagnostic laboratory variables. Sciomics contributed to this study by a scioCD serum analysis targeting different CD surface markers, cytokines and chemokines.

Michel M, Renaud D, Schmidt R, et al. Altered Serum Proteins Suggest Inflammation, Fibrogenesis and Angiogenesis in Adult Patients with a Fontan Circulation. International Journal of Molecular Sciences. 2024; 25(10):5416. 
 

Article | Predicting a severe Covid-19 disease

| April 2023 | New Article: In a protein biomarker development project initiated by Sciomics, we have identified protein biomarker panels predicting development of a severe Covid.19  disease.

Hufnagel K., Fathi A. et al. Discovery and systematic assessment of early biomarkers that predict progression to severe COVID-19 disease. Communications Medicine 3,51 (2023)

Article | Biomarkers for canine mammary neoplasia

| Mai 2023 | New Article: Galadima et al. used the scioCD assay to analyse canine blood samples in the context of mammary neoplasia. The proteins CD20, CD45RA and CD99 were found at altered levels. The findings were validated by Western Blotting and are suggested as novel serum biomarkers.

Galadima et al. Canine Mammary Neoplasia Induces Variations in the Peripheral Blood Levels of CD20, CD45RA, and CD99 (2023) Int. J. Mol. Sci. 24(11)

Article | Selective elimination of immunosuppressive T cells in patients with multiple myeloma

| Feb 2021 | Scientists at Heidelberg University Hospital used our scioCD  platform to profile CD8+SLAMF7+ cell cultures:

"High throughput screening of 351 different cytokines and immune proteins in the supernatants of the T cells cultures revealed strong upregulation of IL-6, IL-8, both vital survival factors for myeloma cells, and CXCL5, a chemokine that could enhance the frequency of CD4 Treg, in the cultures containing CD8+SLAMF7+ cells. IL-2 and IL-5 were upregulated in the control cultures without CD8+SLAMF7+ T cells, highlighting a more activated state in the control group and suggestion IL-6 and IL-8 as potential effector cytokines for the suppressive CD8+SLAMF7+ T cells."

Awwad, M. H. S. et al.  ‘Selective elimination of immunosuppressive T cells in patients with multiple myeloma’, Leukemia 35 2602-2615 (2021)

Testimonials

Tara Sigdel, PhD

Associate Professor, Department of Surgery, University of California San Francisco

"We collaborated with Sciomics GmbH in Germany to analyze proteomics data from blood samples of kidney transplant recipients and liver perfusates during normothermic machine perfusion. Throughout the process, Sciomics provided exceptional support, ensuring timely data delivery and valuable assistance with data analysis. Their expertise and commitment have been instrumental in advancing our research, and we are currently using their data in multiple manuscript submissions. I highly recommend Sciomics for their reliable service and expertise in proteomics."

Product: scioDiscover

Dr. Matthew Wright

Chief Scientific Officer, Kinarus Therapeutics AG, Basel, Switzerland

"We are a small biotech company without our own wet labs. Sciomics recommended a UK CRO that performed cell culture experiments for our studies. Sciomics seamlessly coordinated the transfer of the biologic materials to their facility and performed the scioCD panel to characterize cell surface markers and cytokines in cell lines treated with our small molecule drug candidates. The Sciomics data were instrumental in supporting our IP protection strategy. Their advice was very helpful and they worked with us to extract the most out of the data. We are very satisfied and highly recommend the Sciomics platform and the team."

Product: scioCD

Our protein profiling services

scioDiscover - In depth profiling on the protein level
Knowledge about protein expression levels is of utmost importance to predict toxic effects, estimate adverse effects of drug candidates and to identify new drug targets. Sciomics has a highly optimised…

scioUbi: protein profiling and ubiquitination status
Protein & ubiquitination profiling scioUbi is a high-content protein expression and ubiquitination level analysis. With scioUbi you can analyse more than 1,400 proteins in a single assay.   Features Screen…

scioPhospho: phosphoproteomics and protein profiling service
Discover protein abundance and phosphorylation analysis in one step by our high-throughput scioPhospho platform. Simultaneous detection of protein levels & phosphorylation status of > 1,500 proteins. Our scioPhospho protein phosphorylation…

scioCD - Cell Surface Marker and Cytokine Profiling
Immune response profiling Cellular composition and signalling CD-Marker Expression Profiles       Our scioCD profiling service covers 349 different proteins : up to 141 unique CD-marker molecules up to 119 cytokines and chemokines

scioCyto : Cytokine Profiling
scioCyto is a high-content analysis service for a multiplex cytokine and chemokine profiling on protein level. A great variety of samples such as plasma, tissue, cells or cell culture supernatants can be screened in a high sensitivity and reproducibility
BACK_TO_TOP